4 cysteine in KIV 9 of apo(a) and the C-terminus of apoB-100 (21, 22) . Apo(a) KIV 10 contains a strong lysine-binding site that resembles the lysine-binding site present in plasminogen kringle 4 (23) . Apo(a) may therefore potentially interfere with plasminogen binding to or activation on vascular cells.
Plasminogen is the zymogen form of the serine protease plasmin. The active enzyme plays a key role in the processes of fibrinolysis, cell migration and proliferation, angiogenesis, and inflammation (24) (25) (26) (27) (28) (29) . Plasminogen activation is mediated through proteolytic cleavage of Arg 561 -Val 562 of plasminogen by tissue-type plasminogen activator (tPA) or urokinase-type plasminogen activator (uPA). This process occurs more readily on the cell surface and following conversion of native Glu-plasminogen to Lys-plasminogen (30) (31) (32) . Apo(a) has been shown to inhibit plasminogen activation on the fibrin surface through KV and the strong lysine-binding sites in KIV type 10 (33) . Moreover, apo(a) directly inhibits Glu-to Lys-plasminogen conversion on the fibrin surface with critical roles identified for kringle IV types 5-9 and KV (34) . An apo(a)-mediated decrease in plasmin generation, dependent on apo(a) KIV 9 , has also been shown in the context of smooth muscle cells (SMCs) which results in the inhibition of activation of transforming growth factor β (TGF-β) (35) ; this leads to the stimulation of SMC migration and proliferation (35) (36) (37) .
The strong lysine-binding site present in plasminogen allows for its binding and subsequent activation to occur on various receptors containing carboxyl-terminal lysines including annexin A2 A100A10 heterotetramer, enolase-1, and Plg-R KT (38) . For example, treatment of monocytoid cells with carboxypeptidase B (CpB), which removes carboxyl terminal lysines, leads to a decrease of 64% for plasminogen binding and greater than 95% for plasminogen activation (39 following CpB treatment by approximately 70% whereas a decrease of 90% was observed for plasminogen activation (40) . In another study. binding of plasminogen to human umbilical vein endothelial cells (HUVECs) was also inhibited by ε-aminocaproic acid (ε-ACA), a lysine analogue, by 70-80% (29) .
CpB and active thrombin-activatable fibrinolysis inhibitor (TAFIa) have also been shown to reduce plasminogen activation by 80% on the annexin A2 S100A10 heterotetramer in vitro (41) . In a rat primary hepatocyte model, TAFI knockdown increased the amount of plasmin formed on the cells and promoted proliferation, suggesting the ability of TAFIa to decrease plasminogen binding to hepatocytes (42) . Previous studies have suggested that apo(a) may inhibit pericellular plasminogen activation based on the observation that apo(a) decreases plasminogen binding to endothelial cells and monocytes (43) . Moreover, Lp(a) was reported to inhibit the generation of plasmin activity on endothelial cell surface and not in the fluid phase The construction and expression in human embryonic kidney (HEK293) cells of the rapo(a) variants utilized in this study , 12K, 12ΔV, 17K, 17KΔLBS 10 , and 17KΔV) has been previously described (17, 33, 34, (45) (46) (47) (48) . Variants were purified from conditioned medium, harvested from stably-expressing cell lines, using lysine-Sepharose affinity chromatography as previously described (17, 33, 34, (45) (46) (47) (48) . Protein concentrations were determined spectrophotometrically (17, 33, 34, (45) (46) (47) (48) and assessed for purity by SDS-PAGE under nonreduced and reduced conditions followed by silver staining.
Isolation of Lp(a)
Blood was collected from one healthy volunteer homozygous for a 16K apo(a) isoform.
Blood was collected into BD Vacutainer blood collection tubes containing sodium polyanethol sulfonate and acid citrate dextrose. Plasma was obtained through centrifugation of whole blood at 3,000 × g for 15 min at 4°C. Phenylmethylsufonyl fluoride (PMSF) was added to a final concentration of 0.1 mM and the plasma was rotated at 4°C for 15 min. The plasma was adjusted to a density of 1.063 g/mL with solid sodium bromide and centrifuged at 45,000 × g for 24 hrs at 6°C. The top fraction was removed and the infranatant was adjusted to a density of 1.21 g/ mL with solid sodium bromide. The sample was centrifuged at 45, 000 g for 24 hrs at 6°C and the top layer was isolated and extensively dialyzed against 20 mM Tris-HCl, pH 7.4, containing 150 mM NaCl, 0.01% NaN 3 , and 0.01% EDTA (Buffer A). The sample was then subjected to gelfiltration chromatography over Sepharose CL-4B (Sigma-Aldrich) (2.5 cm × 80 cm column) was assessed by SDS-PAGE under non-reducing and reducing conditions followed by silver staining.
Cell culture
HUVECs were obtained from Clonetics and grown in EGM Complete Medium 
Carboxypeptidase treatment
CpB (Calbiochem) treatment of HUVECs and THP-1 monocytes was performed in HBS-BSA and for THP-1 macrophages in RPMI-BSA. Cells were washed three times and incubated with CpB for one hour at 37°C. Cells were then washed three times followed by assay of plasminogen activation or apo(a)/plasminogen binding as described above. The activity of CpB was measured using anisylazoformylarginine (Calbiochem).
Statistical Methods
Comparisons between data sets were performed using one-way ANOVA with SPSS version 22 software. Statistical significance was presumed at p<0.05. 
RESULTS

Apo(a) directly inhibits plasminogen activation on THP-1 monocytes, THP-1 macrophages, and HUVECs
We examined two different isoforms of apo(a) (12K and 17K) and both were found to inhibit pericellular plasminogen activation in THP-1 monocytes (Fig. 1A,B) . Both isoforms exhibit a similar concentration-dependent effect on inhibition. At 800 nM, 12K and 17K
inhibited plasminogen activation by 57% and 46% respectively. At 800 nM, 12K was not significantly more effective at inhibiting activation compared to 17K. Removal of kringle V in both 12K and 17K not only abolished the inhibitory effect of apo(a) but, surprisingly, caused an increase in plasminogen activation (up to 3.6-and 2.4-fold, respectively; Fig. 1A,B) . Similarly, inactivation of the strong lysine-binding site in apo(a) (17KΔLBS 10 variant) led to a maximal 2.1 fold increase in plasminogen activation (Fig. 1A) . The weak lysine-biding sites of apo(a), present in the KIV 5-8 variant, do not exhibit a significant inhibitory effect at any of the tested concentrations (Fig. 1B) . These results indicate that apo(a) can directly inhibit pericellular plasminogen activation in THP-1 monocytes and imply roles for kringle V and the strong lysinebinding site in KIV type 10 in mediating this effect.
Comparing plasminogen activation in the presence or absence of THP-1 monocytes revealed a 74% decrease in activation in the absence of cells, and this rate was not affected by 17K, 12K or KIV [5] [6] [7] [8] (Fig. 1A,B) . However, 17KΔLBS 10, 17KΔV, and 12KΔV shows a significant increase in plasminogen activation with increasing concentration similar to that in the presence of cells, suggesting that the cell-independent stimulation of plasminogen activation by and 17K, respectively, observed at 800 nM (Fig. 1C,D) . At 800 nM, 12K and 17K were not significantly different in its ability to inhibit activation. Both the strong lysine-binding site in KIV type 10 of 17K (17KΔLBS 10 ) (Fig. 1C) and the kringle V domain (12KΔV) (Fig. 1D) are required for the inhibitory effect of apo(a); as with the THP-1 monocytes, both of these variants resulted in increased, rather than decreased, plasminogen activation. For the 17KΔLBS 10 and 12KΔV variant, this increase again can be ascribed to stimulation of cell-independent plasminogen activation (Fig. 1C,D) . In the absence of THP-1 macrophages, the rate of plasminogen activation was significantly lower (71%) and was unaffected by the presence of 12K and 17K, as was the case for THP-1 monocytes.
Similar experiments were also performed with HUVECs, and with similar results. Apo(a) directly inhibits pericellular plasminogen activation on the surface of HUVECs. A maximal inhibitor effect of 48%, for 12K, and 58%, for 17K was observed at a concentration of 800 nM (Fig. 1E,F) . At 800 nM, 12K was not significantly more effective at inhibiting activation compared to 17K. As with THP-1 monocytes and macrophages, loss of the strong lysine-binding site in KIV 10 or the loss of KV resulted in a cell-independent increase in plasminogen activation (Fig. 1E,F) .
Taken together, the effect of apo(a) on cell-dependent plasminogen activation is remarkably similar for all three cell types tested; moreover, the effect of loss or mutation of To demonstrate that activation of plasminogen observed was dependent on the added tPA and plasminogen and not from the cells themselves or contamination of the r-apo(a), experiments were conducted in the absence of tPA or plasminogen. Omission of either of these components virtually eliminated detectable plasminogen activation in the presence of all three cell types, either in the presence or absence of various r-apo(a) variants (Fig. 2) .
Lp(a) inhibits plasminogen activation on THP-1 monocytes and HUVECs but not on THP-1 macrophages
We examined the ability of Lp(a), purified from human plasma, to inhibit pericellular plasminogen activation. Experiments were conducted using 25 nM plasminogen and 75 nM of Lp(a) or apo(a). Lp(a) and 17K significantly inhibited plasminogen activation by 15% and 35%
on THP-1 monocytes respectively (Fig 3A) . However, Lp(a) did not inhibit plasminogen activation on THP-1 macrophages whereas a decrease of 24% was observed with 17K (Fig 3B) .
Conversely, both Lp(a) and 17K could inhibit plasminogen activation to the same extent, 30%
and 28% respectively, on HUVECs (Fig 3C) . As observed above, plasminogen activation was largely abolished in the absence of tPA or cells, and was not altered with the addition of Lp(a) or 17K ( Fig. 3) Role of carboxyl terminal lysines in cell-dependent plasminogen activation and its inhibition by apo(a)
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It has been previously reported that carboxypeptidase B (CpB) treatment of U937 monocytoid cells reduced plasminogen binding by 64% and cell-enhanced plasminogen activation by 95% (39). These results have been interpreted to mean that plasminogen binding to these residues on cell-surface receptors is required for the acceleration of plasminogen activation by cells. Treatment of THP-1 monocytes with various concentrations of CpB ranging from 0.1 to 100 U/mL results in a significant decrease in plasminogen activation (by a modest 16%) at 100 U/ mL (Fig 4A,B) . Addition of 17K, at 400 nM, at any concentration of CpB results in a decrease in plasminogen activation at all concentrations of CpB; CpB no longer has any significant effect at any concentration in the presence of 17K (Fig. 4A) . Similar results were observed for THP-1 macrophages (Fig. 4C) , except that CpB treatment had a greater effect of plasminogen activation, with significant decreases occurring at 50 and 100 U/mL both in the presence and absence of 17K (Fig. 4C) . Receptors with carboxyl terminal lysines also influence plasminogen activation on HUVECs as a decrease of 24% is observed following treatment with 100 U/mL CpB; a decrease in plasminogen activation owing to CpB was also observed in the presence of 17K although statistical significance was not reached (Fig. 4E) .
Role of carboxyl terminal lysines in plasminogen and apo(a) binding by cells
To attempt to rationalize the effect of CpB on the plasminogen activation of the surface of cells, and its inhibition by apo(a), we examined the ability of plasminogen and apo(a) to bind to THP-1 monocytes, macrophages, and HUVECs, after CpB treatment or in the presence of the lysine analogue ε-ACA. Plasminogen and apo(a) binding (using 400 nM) decreased by 18% and 51% respectively following CpB treatment (100 U/mL) on THP-1 monocytes (Fig. 4B) . Binding (Fig. 4B) . Similarly, in THP-1 macrophages, the addition of ε-ACA reduced plasminogen and apo(a) binding by 91% and 73% respectively (Fig. 4D) . However, a more modest decrease in plasminogen and apo(a) is observed following CpB treatment at 100 U/mL (9% and 13% respectively) (Fig. 4D) . Plasminogen binding to HUVECs also decreases following CpB (100 U/mL) treatment and the addition of ε-ACA by 29% and 75% respectively (Fig. 4F) . Surprisingly, however, apo(a) binding actually increases by 25% and 3% following CpB (100 U/mL) treatment and the addition of ε-ACA respectively (Fig. 4F) . These results indicate that apo(a) binding is partially mediated through receptors with carboxyl terminal lysines on THP-1 macrophages and monocytes but not on HUVECs. However, since CpB treatment had little or no effect on the ability of apo(a) to inhibit plasminogen activation, these lysine-dependent binding events play a minor role, if any, in inhibition of plasminogen activation by apo(a). with its respective plasminogen activators: tPA and uPA. Both tPA and uPA have been shown to be expressed in a variety of cell types, including endothelial cells for tPA (51) and lung, kidney, and several tumour cell lines for uPA (52, 53) . It has been shown that tPA can directly bind to various cell types other than endothelial cells, such as platelets, monocytes, and monocytoid cells (30, 39, 54, 55) . Lp(a) was reported to inhibit plasminogen activation on the surface of resting platelets by inhibiting plasminogen and tPA binding (56) . Therefore, the effects of apo(a) and Lp(a) on tPA-mediated pericellular plasminogen activation on vascular cells were evaluated.
Plasminogen receptors are a heterogeneous and ubiquitously present group of cell surface proteins (38) . Plasminogen receptors have been shown to contain carboxyl-terminal lysine residues that bind plasminogen (38) . Removal of these carboxyl-terminal lysines destroys the ability of this subset of receptors to bind to plasminogen and support its activation (38) .
However, not all plasminogen receptors contain a carboxyl-terminal lysine, with examples of this type being actin, amphoterin, α V β 3 , α M β 2 , and α IIb β 3 (57) . Binding of plasminogen to these receptors presumably converts plasminogen from its native closed conformation into a more open and highly activatable form (38) . The initial plasmin generated on the cell surface begins to catalyze the positive feedback mechanism of converting Glu-to Lys-plasminogen, the latter of which is itself more readily activatable (32) . Furthermore, the plasmin generated on the surface of the cells is protected from its natural inhibitor α 2 -antiplasmin (31). In the context of fibrin, carboxyl terminal lysines have been shown to play a crucial role in regulating plasminogen activation (25, 58) . Hence, the role of carboxyl-terminal lysines on the cell surface was also of interest in this study.
Our studies, for the first time, have directly demonstrated that apo(a) is capable of inhibiting pericellular plasminogen activation. We showed this to be the case with two different isoforms. Interestingly, the 12K and 17K were similar in their ability to inhibit pericellular plasminogen activation. This suggests that the number of KIV type 2 repeats do not dictate the level of inhibition which is in agreement with the findings of Hancock and co-workers in the context of fibrin (33) . On the other hand, studies using a wider array of apo(a) sizes in the context of an intact Lp(a) particle have reported an inverse relationship between isoform size and the ability of Lp(a) to inhibit fibrinolysis and interfere with plasminogen binding to fibrin (59, 60) , while larger Lp(a) isoforms were found to bind with less affinity to THP-1 monocytes (61). Therefore, additional studies are required to assess the possibility that inhibition of pericellular plasminogen activation by apo(a)/Lp(a) is also isoform-size dependent.
The concentration of circulating plasminogen in plasma is 2.2 μM (62) whereas the concentration of Lp(a) varies from 1 to greater than 100 mg/dL, which is approximately equal to 0.01 to 1 μM (4). The molar concentration of plasminogen circulating in the blood is generally greater than that of apo(a); however apo(a) has been shown to accumulate within atherosclerotic lesions and carotid plaques, likely due to its ability to interact with a wide variety of extracellular matrix elements (63) (64) (65) . Importantly, we showed that the ability of apo(a) and Lp(a) to inhibit pericellular plasminogen activation was strictly dependent on the presence of cells (Figs. 1, 3 ).
This likely reflects the ability of apo(a) to influence binding of plasminogen and/or tPA to the cells, although in our own binding studies we were not able to conclusively determine the extent to which apo(a) and plasminogen compete for binding to the cells (Suppl . Fig. 3 ).
Previous studies have identified specific domains of apo(a) that mediate its inhibitory effect on plasminogen activation as well as Glu-plasminogen to Lys-plasminogen conversion on the fibrin surface (33, 34) . Ablation of the strong lysine binding site in kringle IV type 10 was 
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shown to substantially reduce the inhibitory effect of apo(a) whereas removal of kringle V abolished the effect in plasminogen activation on fibrin (33) . Critical roles for kringle IV types 5-9 and kringle V were identified in inhibiting Glu-to Lys-plasminogen conversion on fibrin (34).
Interestingly, apo(a) from baboons and rhesus monkeys do not contain kringle V and are not prone to atherosclerosis (66, 67) . In the case of baboons, the absence of KV renders the Lp(a)
particle incapable of binding to lysine despite the presence of an intact strong LBS in KIV 10 (66).
On the other hand, in our previous studies of SMCs, we found that KIV 9 , but not the strong LBS in KIV 10 , mediated a decrease in TGF-β activation in a mechanism that was dependent on the presence of plasminogen (and thus, presumably, an effect on plasminogen activation) (35) .
Therefore, there may be cell-type differences in the mechanisms through which apo ( 
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The ability of Lp(a) to inhibiting plasminogen activation was also evaluated (Fig. 3) .
Lp(a) was found to inhibit plasminogen activation, to the same extent as 17K, on HUVECs and to a lesser extent on THP-1 monocytes. Plasminogen activation was not inhibited with the low concentration of Lp(a) utilized, ~7 mg/ dL, on THP-1 macrophages. We were restricted to a relatively low concentration of Lp(a) by the concentration of the preparation. The concentration utilized is less than the cardiovascular risk factor of Lp(a) levels >50 mg/ dL and could account for the lack of effect on THP-1 macrophages, possibly due to more rapid uptake of Lp(a) by these cells for example by the apo(a)/Lp(a) receptor identified by Keesler and coworkers (48) .
The importance of carboxyl terminal lysine receptors was determined in vascular and blood cells. Overall, CpB treatment had modest but significant decreasing effects on plasminogen activation and on plasminogen and apo(a) binding (Fig. 4) , with CpB treatment never decreasing binding or activation to below 50% of control. The exception to this was in HUVECs, where apo(a) bound in a manner completely independent of carboxyl-terminal lysines (Fig. 4F) . Addition of the lysine analogue ε-ACA had a more profound effect on plasminogen or apo(a) binding, which may suggest that some binding sites may have represented internal, as compared to carboxyl-terminal, lysine residues. Because of its profound effects on plasminogen conformation, we were unable to assess the effects of ε-ACA on plasminogen activation.
Nonetheless, the available data suggest that the inhibition of plasminogen activation by apo(a) is not dependent on carboxyl-terminal lysines, since CpB treatment of the cells had only a small effect, if any, on the extent of the inhibition. If carboxyl-lysines played a role (such as mediating the binding of apo(a), plasminogen, or tPA required for the inhibition) inhibition by apo(a) would have been eliminated, when in fact it was only minimally impacted (Fig. 4A,C,E) . Indeed, in HUVECs, where apo(a) is able to inhibit plasminogen activation over 50%, apo(a) binding is 20 completely independent of carboxyl-terminal lysines (Fig. 4) . It is reasonable to hypothesize, then, that if lysines do play a role, they would be internal lysines in cell-surface receptors.
Apo(a) has been shown in this current study to play a crucial role in regulating plasminogen activation on vascular cells attributable to kringle V and the strong lysine-binding site in kringle IV type 10. What remains to be determined are the identities of the receptors that presumably mediate these effects. Moreover, it must be evaluated if the inhibition of plasminogen activation by apo(a) results from competition between these proteins for binding sites on cells and/or is a consequence of the ability of apo(a) to inhibit plasminogen activation via interference with the positive feedback mechanism of Glu-to Lys-plasminogen conversion. 
